Logan, UT, United States
Logan, UT, United States

Time filter

Source Type

Fang S.,University of Wisconsin - Madison | Yan M.,Thermofisher Scientific Inc. | Hamers R.J.,University of Wisconsin - Madison
Journal of Power Sources | Year: 2017

The study of inhomogeneous battery failure processes requires proper tools with high spatial resolving power. Here we describe a simple way to adapt industry-standard coin cells to enable in situ Raman mapping of lithium-ion battery materials. We describe the important cell design parameters and validate that the design achieves a uniform potential distribution within the region probed by Raman. We further validate that the cell yields electrical performance characteristics equivalent to a standard, non-modified coin cell. Using this cell, we probe the local charging profiles of LiNi0.5Mn0.3Co0.2O2 (“NMC”) particles during cycling and demonstrate the ability to achieve spatial maps of the Raman spectra. In order to reduce the effects of local topography, we further analyze these data by numerically extracting the local frequency of the A1g vibrational mode, which is sensitive to the local extent of lithiation, and producing spatial maps of the local frequency of the A1g mode. This work demonstrates a way to collect and analyze high quality in situ spectra with an easy-to-implement cell design that can be applied to a wide range of electrode materials. © 2017


RUTHERFORD, N.J. & LOS ANGELES, May 08, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today the successful validation and commercial launch of its next generation sequencing (NGS) assay Liquid::Lung-cfDNA™ to detect lung tumor-derived cell-free DNA (cfDNA) obtained from the plasma fraction of blood. The assay enables analysis of frequently mutated single nucleotide variants and short indels in 11 genes with significant clinical relevance to non-small cell lung cancer (NSCLC). The breakthrough test has a limit of detection (LOD) as low as 0.05% or 1 mutant copy of DNA in a background of 2,000 wild-type copies of DNA. Dr. Barbara Gitlitz, Associate Professor of Clinical Medicine at Keck School of Medicine of USC, and a global thought leader spearheading multidisciplinary lung cancer programs, commented, “As liquid biopsies become a reality in cancer care, integrating them into clinical practice for routine management of cancer patients is pivotal. Having a high-quality provider of novel liquid biopsy assays geared toward lung cancer will help the members of our multidisciplinary treatment teams to come up with the best, individualized treatment plan for each lung cancer patient.” Dr. Gitlitz continued, “By offering a comprehensive panel that provides information for known molecular pathways and has significant clinical evidence, CGI will enable high-quality precision medicine for lung cancer patients." “Over the past few months we have been working closely with several clinical and biopharma customers to uniquely refine this powerful test to meet the needs of routine patient care, and for state-of-the-art clinical trials. Clinical demand for actionable and focused NGS panels for liquid biopsies is increasing in both the community setting and among clinical trials, as liquid biopsies enable new, less-invasive methods for detection and monitoring. By offering a focused liquid biopsy panel that provides information for known molecular pathways and has significant clinical evidence, we are enabling a new era in precision medicine for our customers and their patients, leading to improvements in standard of care in the future”, said Panna Sharma, Chief Executive Officer and President of CGI. Liquid::Lung-cfDNA™ offers several advantages compared to conventional solid tumor samples. Liquid biopsy samples are less invasive to obtain, enabling tumor content to be sampled multiple times and with significantly lower cost compared to traditional tissue sampling. The Liquid::Lung-cfDNA™ assay is based on ThermoFisher Scientific’s Oncomine™ Lung cfDNA assay. It runs on the proven Ion S5™ XL sequencing system and includes the powerful Ion AmpliSeq™ library preparation technology. In addition, the assay is compatible with FFPE samples for possible concordance studies. ABOUT CANCER GENETICS Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. For more information, please visit or follow CGI at: Internet: www.cancergenetics.com Twitter: @Cancer_Genetics Facebook: www.facebook.com/CancerGenetics Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.


Global Metabolomics Market by Detection and Separation Techniques, and Applications, Growth Trends and Forecast to 2021, by iHealthcareAnalyst, Inc. Metabolomics Market by Detection and Separation Techniques, and Applications (Biomarker Discovery, Clinical Toxicology, Drug Assessment, and Nutrigenomics) and Forecast 2017-2021 Maryland Heights, MO, April 15, 2017 --( Browse Metabolomics Market by Detection and Separation Techniques, and Applications (Biomarker Discovery, Clinical Toxicology, Drug Assessment, and Nutrigenomics) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/ The global metabolomics market report estimates the market size (Revenue USD million - 2014 to 2021) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2017 to 2021). The global metabolomics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global metabolomics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global metabolomics market and included in this report are Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Shimadzu Corporation, and Waters Corporation. 1. Technique 1.1. Detection Techniques 1.2. Separation Techniques 2. Application 2.1. Biomarker Discovery 2.2. Clinical Toxicology 2.3. Drug Assessment 2.4. Nutrigenomics 3. Geography (Region, Country) 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. Agilent Technologies Inc. 4.2. Biocrates Life Sciences AG 4.3. Bio-Rad Laboratories, Inc. 4.4. Bruker Corporation 4.5. Human Metabolome Technologies Inc. 4.6. LECO Corporation 4.7. Metabolon Inc. 4.8. Shimadzu Corporation 4.9. ThermoFisher Scientific Inc. 4.10. Waters Corporation To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/metabolomics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 15, 2017 --( PR.com )-- Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. mRNA gene expression data and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function including systems biology and functional genomics that integrates proteomic, transcriptomic, and metabolomic information to provide a better understanding of cellular biology. Metabolomics is an advanced, specialized form of analytical biochemistry that involves the study of chemical processes involving metabolites. Metabolomics enables simultaneous identification and analysis of multiple metabolites in cells, tissues and body fluids. The research funding for metabolomics has increased over the years in the major areas of research includes characterization and identification of novel biomarkers, therapeutic targets, and disease signatures in the area of cancer metabolomics.Browse Metabolomics Market by Detection and Separation Techniques, and Applications (Biomarker Discovery, Clinical Toxicology, Drug Assessment, and Nutrigenomics) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/The global metabolomics market report estimates the market size (Revenue USD million - 2014 to 2021) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2017 to 2021). The global metabolomics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global metabolomics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global metabolomics market and included in this report are Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Shimadzu Corporation, and Waters Corporation.1. Technique1.1. Detection Techniques1.2. Separation Techniques2. Application2.1. Biomarker Discovery2.2. Clinical Toxicology2.3. Drug Assessment2.4. Nutrigenomics3. Geography (Region, Country)3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. Agilent Technologies Inc.4.2. Biocrates Life Sciences AG4.3. Bio-Rad Laboratories, Inc.4.4. Bruker Corporation4.5. Human Metabolome Technologies Inc.4.6. LECO Corporation4.7. Metabolon Inc.4.8. Shimadzu Corporation4.9. ThermoFisher Scientific Inc.4.10. Waters CorporationTo request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/metabolomics-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


Audronis M.,Gencoa Ltd. | Hinder S.J.,University of Surrey | MacK P.,ThermoFisher Scientific Ltd | Bellido-Gonzalez V.,Gencoa Ltd. | And 3 more authors.
Thin Solid Films | Year: 2011

Abstract PET web samples have been treated by magnetically enhanced glow discharges powered using either medium frequency pulse direct current (p-DC) or low frequency high power pulse (HIPIMS) sources. The plasma pre-treatment processes were carried out in an Ar-O2 atmosphere using either Cu or Ti sputter targets. XPS, AFM and sessile drop water contact angle measurements have been employed to examine changes in surface chemistry and morphology for different pre-treatment process parameters. Deposition of metal oxide onto the PET surface is observed as a result of the sputter magnetron-based glow discharge web treatment. Using the Cu target, both the p-DC and HIPIMS processes result in the formation of a thin CuO layer (with a thickness between 1 and 11 nm) being deposited onto the PET surface. Employing the Ti target, both p-DC and HIPIMS processes give rise to a much lower concentration of Ti (< 5 at.%), in the form of TiO2 on the PET treated surface. The TiO2 is probably distributed as an island-like distribution covering the PET surface. Presence of Cu and Ti oxide constituents on the treated PET is beneficial in aiding the adhesion but alone (i.e. without oxygen plasma activation) is not enough to provide very high levels of hydrophilicity as is clear from sessile drop water contact angle measurements on aged samples. Exposure to the plasma treatments leads to a small amount of roughening of the substrate surface, but the average surface roughness in all cases is below 2.5 nm. The PET structure at the interface with a coating is mostly or wholly preserved. The oxygen plasma treatment, metal oxide deposition and surface roughening resulting from the HIPIMS and p-DC treatments will promote adhesion to any subsequent thin film that is deposited immediately following the plasma treatment. © 2011 Elsevier B.V.


Norseen J.,Beth Israel Deaconess Medical Center | Hosooka T.,Beth Israel Deaconess Medical Center | Hosooka T.,Kobe University | Hammarstedt A.,Gothenburg University | And 13 more authors.
Molecular and Cellular Biology | Year: 2012

Retinol-binding protein 4 (RBP4), the sole retinol transporter in blood, is secreted from adipocytes and liver. Serum RBP4 levels correlate highly with insulin resistance, other metabolic syndrome factors, and cardiovascular disease. Elevated serum RBP4 causes insulin resistance, but the molecular mechanisms are unknown. Here we show that RBP4 induces expression of proinflammatory cytokines in mouse and human macrophages and thereby indirectly inhibits insulin signaling in cocultured adipocytes. This occurs through activation of c-Jun N-terminal protein kinase (JNK) and Toll-like receptor 4 (TLR4) pathways independent of the RBP4 receptor, STRA6. RBP4 effects are markedly attenuated in JNK1-/- JNK2-/- macrophages and TLR4-/-, macrophages. Because RBP4 is a retinol-binding protein, we investigated whether these effects are retinol dependent. Unexpectedly, retinol-free RBP4 (apo-RBP4) is as potent as retinol-bound RBP4 (holo-RBP4) in inducing proinflammatory cytokines in macrophages. Apo-RBP4 is likely to be physiologically significant since RBP4/retinol ratios are increased in serum of lean and obese insulin-resistant humans compared to ratios in insulin-sensitive humans, indicating that higher apo-RBP4 is associated with insulin resistance independent of obesity. Thus, RBP4 may cause insulin resistance by contributing to the development of an inflammatory state in adipose tissue through activation of proinflammatory cytokines in macrophages. This process reveals a novel JNK- and TLR4-dependent and retinol- and STRA6-independent mechanism of action for RBP4. © 2012, American Society for Microbiology.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Metabolomics Market USD 1.24 Billion by 2020, Published by iHealthcareAnalyst, Inc. Maryland Heights, MO, November 03, 2016 --( Visit the Metabolomics Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/ Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. mRNA gene expression data and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function including systems biology and functional genomics that integrates proteomic, transcriptomic, and metabolomic information to provide a better understanding of cellular biology. The metabolomics market report estimates the market size (Revenue USD million - 2013 to 2020) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global metabolomics market including company overview, financial snapshot, key products, technologies and services offered, and recent trends in strategic management. The global metabolomics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. 1. Technique 1.1. Detection Techniques 1.2. Separation Techniques 2. Application 2.1. Biomarker Discovery 2.2. Clinical Toxicology 2.3. Drug Assessment 2.4. Nutrigenomics 3. Company Profiles 3.1. Agilent Technologies Inc. 3.2. Biocrates Life Sciences AG 3.3. Bio-Rad Laboratories, Inc. 3.4. Bruker Corporation 3.5. Human Metabolome Technologies Inc. 3.6. LECO Corporation 3.7. Metabolon Inc. 3.8. Shimadzu Corporation 3.9. ThermoFisher Scientific Inc. 3.10. Waters Corporation About Us iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareranalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, November 03, 2016 --( PR.com )-- The global metabolomics market is estimated to reach USD 1.24 Billion in 2020, growing at a CAGR of 15.6% from 2016 to 2020, according to a market research report Metabolomics Market 2013-2020, published by iHealthcareAnalyst, Inc.Visit the Metabolomics Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/metabolomics-market/Metabolomics is the scientific study of chemical processes involving metabolites, whereas metabolome represents the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. mRNA gene expression data and proteomic analyses reveal the set of gene products being produced in the cell, data that represents one aspect of cellular function including systems biology and functional genomics that integrates proteomic, transcriptomic, and metabolomic information to provide a better understanding of cellular biology.The metabolomics market report estimates the market size (Revenue USD million - 2013 to 2020) and key market segments based on detection and separation techniques used, its applications (biomarker discovery, clinical toxicology, drug assessment, and nutrigenomics), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global metabolomics market including company overview, financial snapshot, key products, technologies and services offered, and recent trends in strategic management.The global metabolomics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.1. Technique1.1. Detection Techniques1.2. Separation Techniques2. Application2.1. Biomarker Discovery2.2. Clinical Toxicology2.3. Drug Assessment2.4. Nutrigenomics3. Company Profiles3.1. Agilent Technologies Inc.3.2. Biocrates Life Sciences AG3.3. Bio-Rad Laboratories, Inc.3.4. Bruker Corporation3.5. Human Metabolome Technologies Inc.3.6. LECO Corporation3.7. Metabolon Inc.3.8. Shimadzu Corporation3.9. ThermoFisher Scientific Inc.3.10. Waters CorporationAbout UsiHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareranalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


Barrow D.A.,University of Cardiff | Castell O.K.,University of Cardiff | Sykes N.,University of Cardiff | Myers P.,University of Liverpool | Ritchie H.,ThermoFisher Scientific Ltd
Journal of Chromatography A | Year: 2011

We report the first development of a novel, planar, microfluidic, graphitic carbon separations column utilizing an array of graphitic micropillars of diamond cross-section as the chromatographic stationary phase. 795nm femtosecond laser ablation was employed to subtractively machine fluidic architectures and a micropillared array in a planar, graphitic substrate as a monolithic structure. A sample injector was integrated on-chip, together with fluid-flow distribution architectures to minimize band-broadening and ensure sample equi-distribution across the micro-pillared column width. The separations chip was interfaced directly to the ESI probe of a Thermofisher Surveyor mass spectrometer, enabling the detection of test-mixture analytes following their differential retention on the micro-pillared graphitic column, thus demonstrating the exciting potential of this novel separations format. Importantly, unlike porous, graphitic microspheres, the temperature and pressure resilience of the microfluidic device potentially enables use in subcritical H 2O chromatography. © 2010 Elsevier B.V.


PubMed | Thermofisher Scientific Corporation and CAS Dalian Institute of Chemical Physics
Type: | Journal: Talanta | Year: 2016

A non-derivative method was developed for the qualitative and quantitative analysis of isosteroidal alkaloids from Fritillaria thunbergii. During method development the performance of two universal detectors, the charged aerosol detector (CAD) and evaporative light scattering detector (ELSD), were evaluated. The CAD was found to be 30 to 55 times more sensitive than ELSD enabling the measurement of low levels of reference compound impurities that could not be detected by ELSD. The peak area percent of the reference compound, peimisine, obtained by CAD was 50.10%, but 91.66% by ELSD showing that CAD is suitable to estimate the presence of impurities. The CAD showed good reproducibility with overall intra- and inter-day peak area RSD values of less than 1.8% and 2.7%, respectively and had a linear dynamic range of up to 4 orders of magnitude (0.06-44mg/L) for peimine and peiminine. The optimized method was used for the quantitative analysis of peimine and peiminine from F. thunbergii.


Liu Y.,University of Connecticut Health Center | Charles L.F.,University of Connecticut Health Center | Zarembinski T.I.,Biotime, Inc. | Johnson K.I.,ThermoFisher Scientific Inc. | And 4 more authors.
Macromolecular Bioscience | Year: 2012

These studies provide evidence for the ability of a commercially available, defined, hyaluronan-gelatin hydrogel, HyStem-C™, to maintain both mouse embryonic stem cells (mESCs) and human induced pluripotent stem cells (hiPSCs) in culture while retaining their growth and pluripotent characteristics. Growth curve and doubling time analysis show that mESCs and hiPSCs grow at similar rates on HyStem-C™ hydrogels and mouse embryonic fibroblasts and Matrigel™, respectively. Immunocytochemistry, flow cytometry, gene expression and karyotyping reveal that both human and murine pluripotent cells retain a high level of pluripotency on the hydrogels after multiple passages. The addition of fibronectin to HyStem-C™ enabled the attachment of hiPSCs in a xeno-free, fully defined medium. Animal-free culture methods that retain pluripotent characteristics of stem cells are needed in order to realize the clinical potential of pluripotent stem cells and their derivatives. Our work shows the benefits of commercially available hyaluronan hydrogels to support the maintenance and pluripotency of both mouse embryonic stem cells and human induced pluripotent stem cells throughout prolonged culture. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Loading ThermoFisher Scientific Inc. collaborators
Loading ThermoFisher Scientific Inc. collaborators